# AstraZeneca announce FDA approval of Enhertu in the US

- Link: https://www.directorstalkinterviews.com/astrazeneca-announce-fda-approval-of-enhertu-in-the-us/412801652
- Published: 2019-12-23T07:23:31+00:00
- Author: Amilia Stone

**AstraZeneca** ([LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
and Daiichi Sankyo Company, have today announced that the US Food and Drug Administration
has approved _Enhertu_ for the treatment of adult patients with unresectable or 
metastatic HER2-positive breast cancer who have received two or more prior anti-
HER2 based regimens in the metastatic setting.

This indication is approved under Accelerated Approval based on tumour response 
rate and duration of response. Continued approval for this indication may be contingent
upon verification and description of clinical benefit in a confirmatory trial.

_Enhertu_ is a HER2-directed antibody-drug conjugate (ADC) and the FDA approval 
is based on the results of the registrational Phase II trial DESTINY-Breast01 of
_Enhertu_ (5.4mg/kg) monotherapy in patients with HER2-positive metastatic breast
cancer. All patients received prior trastuzumab, trastuzumab emtansine and 66% had
prior pertuzumab.

The Phase II trial results showed a confirmed objective response rate of 60.3% (
n=111, 95% CI 52.9-67.4) including a 4.3% complete response rate (n=8) and a 56.0%
partial response rate (n=103). A median duration of response of 14.8 months (95%
CI 13.8-16.9) was demonstrated as of 1 August 2019.^(1) In addition, a median progression-
free survival of 16.4 months (95% CI 12.7-not estimable), based upon a median duration
of follow up of 11.1 months, was recently presented at the San Antonio Breast Cancer
Symposium and published online in The New England Journal of Medicine.^(2)

> **José Baselga, Executive Vice President, Oncology R&D, said: **“_Enhertu_ has
> shown impressive results in women with HER2-positive metastatic breast cancer,
> with the majority of women benefiting from treatment and the median duration of
> the response exceeding 14 months. With this first approval, we are proud to bring
> _Enhertu _to patients with high unmet need and we look forward to further exploring
> its potential in additional settings.”

Antoine Yver, Executive Vice President and Global Head, Oncology R&D, Daiichi Sankyo
said: “The approval of _Enhertu_ underscores that this specifically engineered HER2-
directed antibody-drug conjugate is delivering on its intent to establish an important
new treatment for patients with HER2-positive metastatic breast cancer. Since the
beginning of our clinical trial programme four years ago, we have focused on the
opportunity to transform the treatment landscape for patients with HER2-positive
metastatic breast cancer, and we are extremely proud of how quickly we delivered
_Enhertu_ to patients in the US, as _Enhertu_ represents one of the fastest-developed
biologics in oncology.”

The safety of _Enhertu_ has been evaluated in a pooled analysis from both the Phase
II trial DESTINY-Breast01 and the earlier Phase I trial among a total of 234 patients
with unresectable or metastatic HER2-positive breast cancer who received at least
one dose of _Enhertu_ (5.4mg/kg).

The most common adverse reactions (greater than or equal to 20% of patients) were
nausea, fatigue, vomiting, alopecia and constipation. Interstitial lung disease (
ILD)/pneumonitis occurred in 9% of patients. Fatal outcomes due to ILD/pneumonitis
occurred in six patients (2.6%) – two deaths previously reported in the Phase I 
trial and four deaths previously reported in the Phase II trial DESTINY-Breast01.
Following an initial ILD management programme already in place, a further monitoring,
management and educational campaign on ILD/pneumonitis was launched in 2019. Patients
and physicians should be aware of ILD/pneumonitis and patients should be actively
screened and monitored for potential signs and symptoms. If ILD/pneumonitis is identified,
it should be managed with dose modification and steroid treatment according to management
guidelines.^(2)

A regulatory submission for the treatment of patients with HER2-positive metastatic
breast cancer has also been made to Japan’s Ministry of Health, Labour and Welfare
based on the DESTINY-Breast01 and Phase I trials.

AstraZeneca and Daiichi Sankyo are exploring the further potential of _Enhertu_ 
in HER2-breast cancer with three ongoing Phase III trials.

**Financial considerations**

Following US approval, an amount of $125m is due from AstraZeneca to Daiichi Sankyo
as the first milestone payment in HER2-positive breast cancer. Upon approval, this
will be capitalised together with the upfront payment already made earlier in the
year 2019.

Future sales of _Enhertu_ in the US will be recognised by Daiichi Sankyo. AstraZeneca
will report its share of gross profit margin from the sales in the US as collaboration
revenue in the Company’s financial statements. For further details on the financial
arrangements, please consult the announcement of the collaboration agreement from
March 2019.

Share on:
